Synaptogenix Inc (SNPX)

[blu_1]

Over 57 weeks, P300 scores drop dramatically in anyone with moderate Alzheimers disease, a neurodegenerative disease. The fact that 2-73 improved P300 scores above baseline at 57 weeks for its 25 patients in trial is remarkable and not to be merely scoffed at and dismissed as "normal variation".